Phase II Evaluation of Pemetrexed in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian or Primary Peritoneal Carcinoma: A Study of the Gynecologic Oncology Group

摘要: Purpose To estimate the antitumor activity of pemetrexed in patients with persistent or recurrent platinum-resistant epithelial ovarian primary peritoneal cancer and to determine nature degree toxicities. Patients Methods A phase II trial was conducted by Gynecologic Oncology Group. must have had that progressed on platinum-based chemotherapy recurred within 6 months. Pemetrexed at a dose 900 mg/m 2 be administered as an intravenous infusion over 10 minutes every 21 days. Dose delay adjustment permitted for toxicity. Treatment continued until disease progression unacceptable adverse effects. Results From July 6, 2004, August 23, 2006, 51 were entered. total 259 cycles (median, four; range one 19 cycles) administered, 40% receiving six more cycles. Overall, treatment well tolerated. More serious toxicities (grade 3 4) included neutropenia 42%, leukopenia 25%, anemia 15%, constitutional 15% patients. No treatment-related deaths reported. One patient (2%) complete nine (19%) partial responses, median duration response 8.4 Seventeen (35%) stable 4.1 Eighteen (38%) increasing disease. Three (6%) not assessable. Median progression-free survival 2.9 months, overall 11.4 Conclusion has sufficient schedule tested warrant further investigation.